Alterations of Lipid Metabolism in the Heart in Spontaneously Hypertensive Rats Precedes Left Ventricular Hypertrophy

Tomasz K Bednarski1, Monika K Duda2, Pawel Dobrzyn1

  • 1Laboratory of Molecular Medical Biochemistry, Nencki Institute of Experimental Biology, Polish Academy of Sciences, 02-093 Warsaw, Poland.

Cells
|October 14, 2022
PubMed

Insights

Cardiac lipid metabolism disturbances, specifically triglyceride accumulation due to reduced lipolysis and beta-oxidation, contribute to left ventricular hypertrophy and heart dysfunction in spontaneously hypertensive rats.

Area of Science:

  • Cardiovascular Biology
  • Metabolic Research
  • Cardiac Pathophysiology

Background:

  • Cardiac lipid metabolism disturbances are linked to cardiac hypertrophy and heart failure.
  • Spontaneously hypertensive rats (SHRs) exhibit early diacylglycerol accumulation in cardiomyocytes.
  • The precise role of lipid metabolism pathways in SHR cardiac dysfunction remains unclear.

Purpose of the Study:

  • To investigate the impact of lipid synthesis and degradation pathway alterations on left ventricular (LV) hypertrophy development in SHRs.
  • To analyze age-dependent changes in lipid metabolism in SHRs at 6 and 18 weeks.

Main Methods:

  • Comparative analysis of Wistar Kyoto (WKY) and SHR rat models at 6 and 18 weeks of age.
  • Quantification of triglyceride and free fatty acid levels in the left ventricle.
  • Assessment of protein expression for key enzymes and regulators involved in fatty acid synthesis, TG synthesis, beta-oxidation, and lipolysis.

Main Results:

  • SHRs displayed higher LV triglyceride and lower free fatty acid content compared to WKY rats.
  • Reduced expression of de novo fatty acid synthesis proteins was observed in SHR cardiomyocytes.
  • Lower adenosine monophosphate-activated protein kinase phosphorylation and peroxisome proliferator-activated receptor α in 18-week-old SHRs indicated decreased beta-oxidation.
  • Decreased adipose triglyceride lipase (ATGL) activator and increased ATGL inhibitor suggested reduced lipolysis in SHR hearts.

Conclusions:

  • Triglyceride accumulation in SHRs is associated with impaired lipolysis and beta-oxidation in cardiomyocytes.
  • These metabolic alterations contribute to the development of left ventricular hypertrophy and myocardial dysfunction in SHRs.

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
31
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
37
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
52
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.8K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
44
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
46